RE:Eli Lilly's CDK 4/6 in early stage HR+/HER2- breast cancerBesides Pfizer, Roche/Genentech, Merck (MSD), Merck Serono, Incyte and BMS, the potential suitors for ONCY now includes Eli Lilly, Novartis and J&J/Janssen, among others Big Pharma companies that face a looming patent cliff in the next everal years.